Optimal baseline prostate-specific antigen level to distinguish risk of prostate cancer in healthy men between 40 and 69 years of age by 諛뺢꼍湲� et al.
© 2012 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 1011-8934
eISSN 1598-6357
Optimal Baseline Prostate-Specific Antigen Level to Distinguish 
Risk of Prostate Cancer in Healthy Men Between 40 and 69 Years 
of Age
The present study evaluated optimal baseline prostate-specific antigen (PSA) level at 
different ages in order to determine the risk of developing prostate cancer (CaP). We 
analyzed 6,651 Korean men, aged 40-69 yr. The serum PSA levels for these men were 
measured at one institute from 2000 to 2004 and were determined to be between 0-4 ng/
mL. Patients were divided into 4 groups of 25th-percentile intervals, based on initial PSA 
level. Of these, the group with an increased risk was selected, and the optimal value was 
determined by the maximal area under a receiver-operating characteristic curve within the 
selected group. The risk of CaP diagnosis was evaluated by Cox regression. The mean 
follow-up period was 8.3 yr. CaP was detected in 27 of the 6,651 subjects. CaP detection 
rate was increased according to age. The optimal PSA value to distinguish the risk of CaP 
was 2.0 ng/mL for 50- to 69-yr-olds. Patients with a baseline PSA level greater than the 
optimal value had a 27.78 fold increase in the prostate cancer risk. Baseline PSA values are 
useful for determining the risk of developing CaP in Korean men for 50- and 69-yr-old. 
We suggest that PSA testing intervals be modified based on their baseline PSA levels. 
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INTRODUCTION
The American Urological Association (AUA) and American Can-
cer Society (ACS) recommend that prostate cancer screening 
begin at 50 yr of age for men with an average risk of prostate can-
cer (CaP) and even earlier for men with a higher risk for pros-
tate cancer due to risk factors, such as a positive family history 
in a first-degree relative or African American heritage (1, 2). Pros-
tate cancer screening is performed for the early detection of cur-
able prostate cancer. Prostate cancer deaths are seen in men as 
young as 35 to 44 yr of age, according to Surveillance, Epidemi-
ology, and End Results (SEER) data. These deaths indicate that 
men younger than the recommended screening age of the AUA 
and ACS for the early detection of prostate cancer can also be 
affected by the disease. Therefore, depending on the risk for de-
veloping prostate cancer, the prevention and detection strategy 
should be adjusted to include younger men. To assess the risk of 
prostate cancer, baseline prostate-specific antigen (PSA) levels 
are used. In 2005, Whittemore and colleagues (3) reported that 
PSA levels in young adults were useful predictors of CaP detec-
tion. Loeb et al. (4), reported that the baseline PSA levels for men 
in their 40s were a stronger predictor of CaP risk than ethnicity, 
family history, or digital rectal examination findings. Ultimately, 
the National Comprehensive Cancer Network (NCCN) recom-
mended a baseline PSA test for all men, starting at 40 yr of age, 
in order to assess the risk for CaP. It has been determined that 
PSA level distributions differ based on ethnicity and age (5-7). 
Therefore, research should be conducted taking into account 
ethnic differences. 
 Based on healthy-screened Korean men with PSA levels be-
tween 0-4 ng/mL, we assessed the optimal baseline PSA levels 
for the prediction of the risk of developing prostate cancer in Ko-
rean men.
MATERIALS AND METHODS
Study population
Between January 2000 and July 2004, a total of 6,651 men be-
tween the ages of 40 and 69 yr with baseline PSA levels between 
0-4 ng/mL during routine health checkups were enrolled in the 
study. Patients who had a previous diagnosis of CaP, a history of 
prostate surgery, or who had received 5-alpha reductase inhibi-
tors within three months were excluded from the study. In July 
2009, cases of CaP in enrolled patients were identified using data 
available from the Korean National Health Insurance Corpora-
tion (NHIC) website, which links to the Korean Severe Patient 
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Registry. We typed in the hospital serial number in the patient 
information query of order communicating system at the hos-
pital administration office so that their registration in Korean 
Severe Patient Registry could be confirmed. This registry includes 
data for over 99% of all cancer cases diagnosed in Korea (8). Of 
our total study sample of 6,651 men, 17 died due to diseases other 
than prostate cancer during the study period. 
Assessment of risk
Patients were divided into 4 groups at 25th percentile intervals 
based on initial PSA, as carried out by Whittemore et al. (3). Of 
these, the group that had an increased risk was selected, and the 
optimal PSA value was determined using the maximal area un-
der the curve (AUC) of a receiver-operating characteristic curve 
(ROC) within the selected group. The risk of developing prostate 
cancer in the enrolled men was studied based on the optimal 
PSA value. In this analysis, when more than one PSA measure-
ment was available for a subject within an age-decade, the ear-
liest measurement was used as the baseline PSA level for deter-
mining risk.
PSA testing
Serum PSA levels were measured using an Elecsys 170 assay 
(Roche Diagnostics, Mannheim, Germany). Vacutainer tubes 
were used (Becton Dickinson, Oxford, UK) for blood collection, 
and the specimen was centrifuged after venipuncture and col-
lection. After centrifugation, the specimens were immediately 
frozen at -70°C and were assessed for PSA within three days.
Statistics
All statistical tests were two-sided. A P value < 0.05 was consid-
ered statistically significant (SAS software, version 9.1). A Kaplan-
Meier survival analysis was performed to estimate prostate can-
cer-free probability, with time considered as a function of the 
baseline PSA level. Subjects without cancer were censored at 
death or July 2009. A log-rank statistical test was used to com-
pare the Kaplan-Meier survival curves among the PSA groups. 
A Cox proportional hazards regression model was used to ex-
amine the long-term relationship between baseline PSA level 
and prostate cancer risk. Comparison of the performance of 
each Cox model was calculated by C statistics (area under the 
ROC curve). The Hazard ratio (HR) and 95% confidence inter-
vals (CI) were estimated using the Cox regression model, with a 
PSA level lower than the cutoff value treated as the reference 
group. 
Ethics statement
The institutional review board of Gangnam Severance Hospital 
reviewed summary and full text of the present clinical research 
proposal, proposal for waiver review, and proposal for waiver 
informed consent. The board approved this clinical study (3-
2010-0033) and waived informed consent due to its nature of 
retrospective research.
Table 1. Characteristics of baseline PSA of study participants
Age (yr)
Baseline PSA level  
(ng/mL)
No. of men No. of cancer cases Cancer detection rate 
Mean follow up year to detect 
prostate cancer (range)
40-49 (n = 3,417) 0.00-0.49
0.50-0.99
1.00-1.49
1.50-1.99
2.00-2.49
2.50-2.99
3.00-3.49
3.50-3.99
Mean
619
1,677
726
227
93
45
15
15
  
0
1
1
0
1
0
0
0
  
0.0%
0.1%
0.1%
0.0%
1.1%
0.0%
0.0%
0.0%
0.1%
  
8.5
9.4
 
7.2
 
 
  
8.7 (9.2-9.4)
50-59 (n = 2,234) 0.00-0.49
0.50-0.99
1.00-1.49
1.50-1.99
2.00-2.49
2.50-2.99
3.00-3.49
3.50-3.99
Mean
408
1,013
474
174
88
41
21
15
  
0
2
1
1
3
2
3
3
  
0.0%
0.2%
0.2%
0.6%
3.4%
4.9%
14.3%
20.0%
0.7%
  
5.9 (5.9-6.0)
8.6
6.2
6.5 (4.7-8.3)
6.5 (6.3-6.6)
5.2 (2.2-8.4)
4.8 (2.9-7.3)
6.3 (2.2-8.6)
60-69 (n = 1,009) 0.00-0.49
0.50-0.99
1.00-1.49
1.50-1.99
2.00-2.49
2.50-2.99
3.00-3.49
3.50-3.99
Mean
143
394
207
110
73
37
18
18
 
0
1
0
2
1
3
0
2
 
0.0%
0.3%
0.0%
1.8%
1.4%
8.1%
0.0%
11.1%
0.9%
  
7.5
 
5.7 (2.9-8.3)
8.4
4.4 (3.6-5.3)
 
4.7 (2.7-6.7)
6.2 (2.7-8.4)
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RESULTS
At baseline, the patients had a mean age of 50 yr and a mean PSA 
value of 0.83 ng/mL. The median PSA levels were 0.72, 0.81, and 
0.93 ng/mL, and the third quartile PSA levels were 1.08, 1.23, 
and 1.51 ng/mL for men in their 40s, 50s, and 60s, respectively. 
The mean follow-up period was 8.3 yr. CaP was detected in 27 
of the 6,651 subjects. After initial PSA measurement, prostate 
cancer was discovered after at least 2.2 yr in men in their 50s and 
2.7 yr in men in their 60s. CaP detection rates increased accord-
ing to the baseline PSA from their 50s (Table 1). 
 When all subjects were classified into 4 groups based on 25th 
percentile intervals of baseline PSA level, the risk of prostate can-
cer significantly increased in men with a baseline PSA level great-
er than the 75th percentile. However, men in their 40s did not 
have a significantly increased risk of prostate cancer (Fig. 1). 
Above the 75th percentile of the baseline PSA level, the cut-off 
value with the greatest sensitivity (92%) and specificity (80%) was 
2.0 ng/mL (93 percentile) for men in their 50s and 60s (Fig. 2).
 As compared with the group with a baseline PSA level less 
than the cut-off value, the group with a PSA level higher than 
the cut-off value had a 27.78-fold increased risk for diagnosis of 
CaP in their 50s and 60s (P < 0.001). The age-adjusted CaP haz-
ard ratio was also significantly increased 25.76-fold for men in 
their 50s and 60s.
 However, when the cut-off value was set at the median base-
line PSA, the risk of CaP was a 13.9-fold increase for men in their 
50s and 60s (P = 0.01). 
DISCUSSION
Based on our results, the median baseline PSA levels were 0.72 
ng/mL, 0.81 ng/mL, and 0.93 ng/mL for men in their 40s, 50s, 
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Fig. 1. Cumulative prostate cancer-free survival according to the age and baseline PSA percentile. Survival curves for men aged (A) 40 to 69 yr, (B) 40 to 49 yr, (C) 50 to 59 yr 
and (D) 60 to 69 yr. Markers represent  prostate cancer and censored cases. With time, prostate cancer incidence increased significantly in men with a baseline PSA more than 
the 75th percentile (reverse triangle), except for men in their 40s (log-rank test for trend).
Fig. 2. Trend of the area under the curve according to a baseline PSA cut-off value 
greater than the median PSA level in men 50 to 69 yr old. AUC, area under the curve; 
PSA, prostate-specific antigen.
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and 60s, respectively. When the ages of the subjects were restrict-
ed to between 50 and 69 yr old, the median baseline PSA of the 
selected subjects was 0.85 ng/mL. These results are similar to 
those of previous studies (5, 6). Men in their 40s did not have a 
significant baseline PSA level that would determine their risk of 
prostate cancer. However, for those in their 50s and 60s, the group 
with a baseline PSA higher than the 75th percentile had a signif-
icantly increased risk, as compared to their age-specific lowest 
quartile baseline PSA level. Of these, the baseline PSA level 2.0 
ng/mL had a maximal discriminative value according to the re-
ceiver-operating characteristic curve, when the subjects who 
were older than 50 yr old were divided into two groups based 
on their baseline PSA level (cutoff level of 2.0 ng/mL). As com-
pared with the group with a baseline PSA level less than the cut-
off value of 2.0 ng/mL, the group with a PSA level higher than 
the cut-off value had a 27.78-fold increased risk for diagnosis of 
CaP in the mean 8.3 yr of follow up. However, despite a relative-
ly high risk for diagnosis of CaP, the median baseline PSA value 
(0.85 ng/mL) did not suggest a more efficient discriminative val-
ue for determining the risk for diagnosis of CaP than the base-
line PSA value, 2.0 ng/mL. We believe that PSA screening every 
one year in men older than 50 yr old with more than 2.0 ng/mL 
of baseline PSA value would lead to a considerable decrease in 
the number of screening visits, associated costs and stress, while 
carrying minimal risk for missing aggressive cancer at a curable 
stage. 
 In men over the age of 50 yr, the group with a baseline PSA 
higher than the 75th percentile had a significantly increased risk, 
as compared to their age-specific lowest quartile baseline PSA 
level (Fig. 1). All values of last quartile (from 1.2 ng/mL to 4.0 ng/ 
mL) had an increased risk as compared with lowest quartile val-
ues however, of these 2.0 ng/mL had a maximal AUC. 
 PSA level is also used as a screening tool to detect prostate can-
cer. Most diagnostic tools have cut-off points for maximal speci-
ficity and sensitivity. Therefore, it was important to determine 
the PSA value with the maximal AUC according to the receiver-
operating characteristic curve. When the data were evaluated 
for men older than 50 yr old, and in regards to the median base-
line PSA, there was not sufficient area under the curve to provide 
Table 2. A comparison of risk of developing prostate cancer in Korean men with base-
line PSA values by age
Age (yr)
PSA cutoff level 
(ng/mL)
 HR‡ (95% CI)   P
50-69 0.85* 14.56 (2.97-50.05) 0.0006
1.31† 17.09 (5.90-49.45) < 0.0001
2   27.78 (10.23-50.72) < 0.0001
2.5   25.17 (11.01-47.74) < 0.0001
3 24.15 (9.12-58.80) < 0.0001
*median baseline PSA value; †75th percentile of baseline PSA value; ‡HR estimated by 
Cox regression model for comparisons with the reference group (lower than cut-off). 
PSA, prostate-specific antigen; HR, hazard ratio; CI, confidence interval.
a cut-off value. At this point, the AUC was approximately 0.7. 
 Ultimately, the optimal baseline cut-off PSA value for determin-
ing the risk of prostate cancer was 2.0 ng/mL for men in their 
50s and 60s. The cut-off value for men in their 50s and 60s was 
slightly higher than those of western populations (9, 10). This 
difference is likely due to the lower rate of developing CaP in 
Korean men in this study. If the overall incidence of CaP increas-
es, the cut-off value of baseline PSA may decrease, as has been 
observed in statistic results based on Western populations (11). 
 Upon reviewing the results of similar studies, we found that 
several authors reported that the median baseline PSA was used 
as a cut-off value for risk stratification in Western populations. 
They reported a dozen-fold increased risk of CaP diagnosis (12, 
13). However, the authors did not evaluate the lowest and high-
est quartile value of baseline PSA. Therefore, it is unknown which 
quartile had the greater affect. 
 Tang et al. (14) recently reported a 1.5 ng/mL cut-off value for 
estimating the risk of developing prostate cancer, which was not 
the median PSA value. However, their study included white and 
black men. 
 Schroder et al. (15) studied the probability of progression of 
PSA in the Netherlands. PSA progression to more than 3.0 ng/
mL occurred in 0.9%, 9.3%, and 48.6% of men who presented 
PSA values less than 1.0, 1 to 1.9 and 2 to 2.9 ng/mL, respective-
ly. They concluded that men who had a baseline PSA level less 
than 2.0 ng/mL rarely had a chance to progress CaP. Ito et al. (16) 
also wanted to know the probability of developing CaP in Japa-
nese compared to the Netherlands. However, they did not find 
any difference of developing prostate cancer over a 4-yr study 
period. The authors investigated the relationship between base-
line PSA and the cumulative probability of increased PSA above 
4.0 ng/mL to find the probability of developing prostate cancer 
indirectly. However, the cumulative probability of increased PSA 
above 4.0 ng/mL may overestimate the risk of developing screen 
detectable prostate cancer, because some men may have a non-
cancer-related PSA increase.
 Wright et al. (17) also reported that baseline PSA levels reflect-
ed a long-term risk of prostate enlargement. However, the sam-
ple size of that study was too small to produce a meaningful cut-
off level.
 Unlike other studies, our study did not reveal a significant dif-
ference in the risk of prostate cancer among the 4 quartile groups 
at ages in the 40s. This is probably because of the low incidence 
of prostate cancer in Korean men.
 According to the Surveillance, Epidemiology, and End Results 
data, CaP deaths occur in North American men between the ages 
of 35 and 44 yr (18). Similarly, CaP deaths are also beginning to 
occur in Korean men younger than 50 yr, and there is an increas-
ing trend toward even younger men dying from CaP (19). The 
age-adjusted incidence rate is 159.3 per 100,000 men per year 
in the US population (18) as opposed to 20.0 in the Korean pop-
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ulation (20). This ethnicity-based difference may be attributed 
to two factors discussed below. First, a relatively low overall CaP 
incidence rate in Korean men may lead to a lower incidence at 
the 40s, as prostate cancer requires time to manifest. Therefore, 
if the overall incidence is reduced, prostate cancer occurrences 
may be reduced in younger age groups. Second, Korean men 
ultimately may not have a risk of CaP due to a lack genetic his-
tory for familial prostate cancer and/or lack of African heritage, 
as compared to individuals in Western populations (21), both 
of which are factors associated with the development of prostate 
cancer at earlier ages. Based on these results, baseline PSA test-
ing beginning at age 40 yr is not yet an effective screening strat-
egy for Korean men. We suggest that baseline screening should 
begin at age 50 for Korean men. We believe that annual screen-
ing in men with more than 2.0 ng/mL of baseline PSA level is a 
reasonable cutoff value. 
 There were some limitations to this study. First, subjects of the 
study were participants of a routine health check-up. Therefore, 
these results might not be the same as those seen in the normal 
population. Second, digital rectal examination (DRE) was not 
included in the screening procedure. When PSA values are low, 
a positive DRE result is associated with CaP in only 3% to 5% of 
the cases (22, 23). Vis et al. (24) calculated that one would have to 
perform 289 DREs to find one case of clinically significant CaP in 
patients with a PSA level less than 3.0 ng/mL. Therefore, we as-
sumed that the omission of DRE did not greatly affect our results. 
 Third, the presence of CaP was not confirmed by a pathologic 
report based on prostate biopsy, but rather from data from a can-
cer registry maintained by NHIC. Therefore, we were unable to 
access complete pathologic information for all study participants. 
Finally, we did not know exactly the compliance of prostate bi-
opsy in participants. In a prostate cancer prevention trial (PCPT), 
2,950 of 3,568 men with a prostate-specific antigen level < or =  
4.0 ng/mL per underwent prostate biopsy at the end of the study 
(25). According to the PCPT, 14.6% of subjects did not agree to 
prostate biopsy. We believe that our study might have a similar 
compliance rate. These should be considered in interpreting 
our results. Therefore, we believe that more long term and full 
pathologic data based results will be necessary to reveal the ef-
ficacy of baseline PSA testing in Korean men. 
 Baseline PSA values are useful for determining the risk of de-
veloping prostate cancer in Korean men between 50 and 69 yr 
old. We recommend that men between 50 and 69 yr old should 
have their baseline PSA levels measured. Moreover, we believe 
that a baseline PSA cutoff value of 2.0 ng/mL is a discriminative 
value for determining the risk of developing prostate cancer in 
Korean men 50 yr old or older. Therefore, we suggest that PSA 
testing intervals be modified for men older than 50 yr based on 
their baseline PSA levels.  
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